Print page
Email page
Download PDF
« Previous Release | Next Release »
COLUMBIA, Md., Jun 08, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Celsion's President and CEO, will present at the 8th Annual Needham Life Sciences Conference on Wednesday, June 10th at 2:00 P.M. ET at the New York Palace Hotel in New York City. The Needham Life Sciences Conference is a leading industry event attracting over 100 healthcare companies. The conference provides participating companies with the opportunity to present to institutional investors and industry experts.
A live audio webcast of the presentation will be available by visiting Celsion's website at www.celsion.com. To listen to the live presentation, please go to Celsion's website prior to the start of the presentation to register, download and install the necessary audio software. An archive of the presentation will be available on the Company's website for 30 days.
About Celsion
Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox(R) to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.
For more information on Celsion, visit our website: http://www.celsion.com
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Celsion Corporation
Celsion Corporation
Sean Moran, 410-290-5390
Senior Vice President and Chief Financial Officer
smoran@celsion.com
or
The Trout Group
Marcy Nanus, 646-378-2927
mnanus@troutgroup.com
Copyright Business Wire 2009
